Denali Therapeutics Inc. financial data

Symbol
DNLI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
161 Oyster Point Blvd., South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.46 K % +333%
Debt-to-equity 10.1 % -77.7%
Return On Equity -11.5 % +71.4%
Return On Assets -10.4 % +62.2%
Operating Margin -65.5 % +83.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 143 M shares +4.18%
Common Stock, Shares, Outstanding 143 M shares +4.22%
Entity Public Float 2 B USD +33.3%
Common Stock, Value, Issued 1.71 M USD +1.48%
Weighted Average Number of Shares Outstanding, Basic 149 M shares +9.43%
Weighted Average Number of Shares Outstanding, Diluted 149 M shares +9.43%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 295 M USD +191%
Revenue from Contract with Customer, Excluding Assessed Tax 295 M USD +201%
Research and Development Expense 402 M USD +0.16%
General and Administrative Expense 101 M USD +6.71%
Operating Income (Loss) -194 M USD +51%
Nonoperating Income (Expense) 51.5 M USD +249%
Income Tax Expense (Benefit) 30 K USD +42.9%
Net Income (Loss) Attributable to Parent -137 M USD +63%
Earnings Per Share, Basic -0.94 USD/shares +67.2%
Earnings Per Share, Diluted -0.94 USD/shares +67.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.6 M USD -11.1%
Marketable Securities, Current 876 M USD -28.2%
Assets, Current 974 M USD -26.5%
Property, Plant and Equipment, Net 46.9 M USD +11.3%
Operating Lease, Right-of-Use Asset 25.3 M USD -9.77%
Other Assets, Noncurrent 44.6 M USD +218%
Assets 1.58 B USD +12.2%
Accounts Payable, Current 11.9 M USD
Employee-related Liabilities, Current 8.05 M USD +9.34%
Accrued Liabilities, Current 5.99 M USD
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 82.6 M USD -78.9%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 43 M USD -14.9%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 126 M USD -71.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.3 M USD +48.5%
Retained Earnings (Accumulated Deficit) -1.22 B USD -12.7%
Stockholders' Equity Attributable to Parent 1.46 B USD +50.6%
Liabilities and Equity 1.58 B USD +12.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -114 M USD -93.2%
Net Cash Provided by (Used in) Financing Activities 500 M USD +31089%
Net Cash Provided by (Used in) Investing Activities -453 M USD -389%
Common Stock, Shares Authorized 400 M shares 0%
Common Stock, Shares, Issued 143 M shares +4.22%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -66.5 M USD +55.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 62.1 M USD -10.7%
Deferred Tax Assets, Valuation Allowance 376 M USD +13%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 388 M USD +11.6%
Operating Lease, Liability 50.5 M USD -11.5%
Payments to Acquire Property, Plant, and Equipment 2.15 M USD -22.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -136 M USD +62.6%
Lessee, Operating Lease, Liability, to be Paid 62.6 M USD -15.1%
Property, Plant and Equipment, Gross 91.6 M USD +12.7%
Operating Lease, Liability, Current 7.51 M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.2 M USD +3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.8 M USD +3.29%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12 M USD -27.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6 M USD +3.3%
Deferred Tax Assets, Operating Loss Carryforwards 89.3 M USD +32.3%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 30 K USD +42.9%
Preferred Stock, Shares Authorized 40 M shares 0%
Unrecognized Tax Benefits 26.2 M USD +35.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 13 M USD +3.31%
Operating Lease, Payments 11.1 M USD -3.67%
Additional Paid in Capital 2.67 B USD +30.5%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 0 USD -100%
Current Federal Tax Expense (Benefit) 0 USD
Depreciation, Depletion and Amortization 2.16 M USD -78.5%
Deferred Tax Assets, Net of Valuation Allowance 12 M USD -18.7%
Share-based Payment Arrangement, Expense 108 M USD +5.97%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%